E-LIB Suche - Ergebnisse für: Battista, Teresa

1

Long-Term Efficacy of Guselkumab in an Adolescent Hidradeni..:

Martora, Fabrizio ; Battista, Teresa ; Potestio, Luca...
Clinical, Cosmetic and Investigational Dermatology. 17 (2024) - p. 483-487 , 2024

Link: https://doi.org/10.2147/..

2

Biological Therapy for Psoriasis in Cancer Patients: An 8-Y..:

Battista, Teresa ; Gallo, Lucia ; Martora, Fabrizio...
Journal of Clinical Medicine. 13 (2024) 7 - p. 1940 , 2024

Link: https://doi.org/10.3390/..

3

Secukinumab for Severe Hidradenitis Suppurativa in a Patien..:

Martora, Fabrizio ; Annunziata, Maria Carmela ; Potestio, Luca...
Clinical, Cosmetic and Investigational Dermatology. 17 (2024) - p. 1275-1279 , 2024

Link: https://doi.org/10.2147/..

4

Viral reactivation following COVID-19 vaccination: a review..:

Martora, Fabrizio ; Megna, Matteo ; Battista, Teresa...
Clinical and Experimental Dermatology. , 2024

Link: https://doi.org/10.1093/..

5

Secukinumab in Hidradenitis Suppurativa Patients Who Failed..:

Martora, Fabrizio ; Marasca, Claudio ; Cacciapuoti, Sara...
Clinical, Cosmetic and Investigational Dermatology. 17 (2024) - p. 159-166 , 2024

Link: https://doi.org/10.2147/..

6

Reply to "Improved clinical effectiveness of adalimumab whe..:

Martora, Fabrizio ; Potestio, Luca ; Battista, Teresa.
Journal of the European Academy of Dermatology and Venereology. , 2024

Link: https://doi.org/10.1111/..

7

Management of Psoriasis Patients with Serious Infectious Di..:

Megna, Matteo ; Lauletta, Giuseppe ; Tommasino, Nello...
Advances in Therapy. 41 (2024) 6 - p. 2099-2111 , 2024

Link: https://doi.org/10.1007/..

8

Risk Factors for Psoriasis Flares: A Narrative Review:

Potestio, Luca ; Lauletta, Giuseppe ; Tommasino, Nello...
Psoriasis: Targets and Therapy. 14 (2024) - p. 39-50 , 2024

Link: https://doi.org/10.2147/..

9

The Role of Interleukin 23/17 Axis in Psoriasis Management:..:

Potestio, Luca ; Martora, Fabrizio ; Lauletta, Giuseppe...
Clinical, Cosmetic and Investigational Dermatology. 17 (2024) - p. 829-842 , 2024

Link: https://doi.org/10.2147/..

10

Guselkumab, Risankizumab, and Tildrakizumab in the Manageme..:

Martora, Fabrizio ; Scalvenzi, Massimiliano ; Battista, Teresa...
Clinical, Cosmetic and Investigational Dermatology. 16 (2023) - p. 2525-2536 , 2023

Link: https://doi.org/10.2147/..

11

Reply to "Dalbavancin for the treatment of severe hidradeni..:

Martora, Fabrizio ; Ruggiero, Angelo ; Potestio, Luca..
Journal of the European Academy of Dermatology and Venereology. 37 (2023) 11 - p. , 2023

Link: https://doi.org/10.1111/..

12

Use of Biological Therapies for the Management of Pustular ..:

Megna, Matteo ; Camela, Elisa ; Ruggiero, Angelo...
Clinical, Cosmetic and Investigational Dermatology. 16 (2023) - p. 1677-1690 , 2023

Link: https://doi.org/10.2147/..

13

Long-Term Efficacy and Safety of Risankizumab for Moderate ..:

Megna, Matteo ; Ruggiero, Angelo ; Battista, Teresa...
Journal of Clinical Medicine. 12 (2023) 9 - p. 3233 , 2023

Link: https://doi.org/10.3390/..

14

Nail Psoriasis: An Updated Review of Currently Available Sy..:

Battista, Teresa ; Scalvenzi, Massimiliano ; Martora, Fabrizio..
Clinical, Cosmetic and Investigational Dermatology. 16 (2023) - p. 1899-1932 , 2023

Link: https://doi.org/10.2147/..

15

Advancing dermatology: embracing the power of artificial in..:

Potestio, Luca ; Martora, Fabrizio ; Villani, Alessia...
Clinical and Experimental Dermatology. 49 (2023) 7 - p. 730-731 , 2023

Link: https://doi.org/10.1093/..